Effectiveness and safety of programmed cell death-1 inhibitor in the treatment of advanced non-HBV non-HCV-related hepatocellular carcinoma
10.3969/j.issn.1001-5256.2022.12.015
- VernacularTitle:程序性细胞死亡受体-1抑制剂治疗中晚期非病毒性相关肝癌的效果及安全性分析
- Author:
Haonan LIU
1
;
Yuqin WANG
2
;
Meng WU
1
;
Tong LU
3
;
Yang ZHAO
1
;
Zhengxiang HAN
1
Author Information
1. Department of Oncology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221000, China
2. Department of General Surgery, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221000, China
3. Department of Gastroenterology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221000, China
- Publication Type:Original Articles_Liver Neoplasms
- Keywords:
Liver Neoplasms;
Programmed Cell Death 1 Receptor;
Response Evaluation Criteria in Solid Tumors;
Drug-Related Side Effects and Adverse Reactions
- From:
Journal of Clinical Hepatology
2022;38(12):2761-2766
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical effectiveness and adverse events of domestic programmed cell death -1 (PD-1) inhibitor in the treatment of advanced non-HBV non-HCV-related hepatocellular carcinoma (NBNC-HCC). Methods A totals of 31 patients with advanced NBNC-HCC who received domestic PD-1 inhibitor in the Affiliated Hospital of Xuzhou Medical University from June 2019 to February 2022 were retrospectively enrolled and their clinicopathological data were retrieved from their medical records and analyzed, i.e., the time to disease progression (TTP), disease control rate (DCR), objective response rate (ORR), and adverse events were recorded and statistically analyzed. The Kaplan-Meier method was used for survival analysis. Results Among these 31 patients, only one achieved the complete response and four achieved the partial response, and six had the stable disease, but 20 showed a disease progression, resulting in an ORR of 16.1% and a (DCR of 35.5%. The median TTP was 7.2 months [95% confidence interval: 6.4-8.0) months]. The incidence of adverse events was 61.30% and the common adverse events were skin rash (29.03%) and hypertension (22.58%). However, there was no grade 4 adverse reactions or related death in these patients. Conclusion Advanced NBNC-HCC patients had a relative weak response to the PD-1 inhibitor although the adverse events were controllable. Future multi-center prospective clinical trials are needed to validate the data.
